The coronavirus vaccine from Sanofi and GlaxoSmithKline will receive up to $2.1 billion from Operation Warp Speed — here's how it compares to other candidates

Joel Saget/AFP/Getty Images

• Drug makers Sanofi and GlaxoSmithKline are set to receive up to $2.1 billion in funding for their potential coronavirus vaccine.
• The funding comes from Operation Warp Speed, the Trump administration's effort to deliver 300 million doses of a safe, effective coronavirus vaccine by January 2021. 
• Sanofi recently moved up the date of its first clinical trial to September.
• Other candidates like Moderna's have already reached phase 3 of their trials. 
• Visit Business Insider's homepage for more stories.

The US is assembling an army of vaccine candidates in the hopes that one will be successful in warding off the coronavirus. The latest candidate to get government funding hails from two of the world's largest vaccine makers: Sanofi and GlaxoSmithKline. 

On Friday, the companies announced that their protein-based vaccine will receive funding from Operation Warp Speed, the Trump administration's effort to deliver 300 million doses of a safe, effective coronavirus vaccine by January 2021. The program's goal is to manufacture promising vaccine candidates in large quantities while clinical trials are still ongoing.

See the rest of the story at Business Insider

NOW WATCH: 4 potential coronavirus treatments that researchers are working on right now

See Also:

• A 20-year study on dozens of vaccines finds they are safer than 'almost any other modern medical intervention'
• Moderna's coronavirus vaccine just started its phase 3 trial — the first in the US. Here's how it'll work.
• You're going to need more than one coronavirus shot. One dose of a vaccine probably won't be enough, experts say.

from Feedburner https://ift.tt/2CYOsL8